Loading
Latest filing published 10 Dec 2025 for Adverum Biotechnologies, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Setareh Seyedkazemi in Adverum Biotechnologies, Inc., where the filings describe the role as senior executive. In total, 11 filings cover trades dated from 23 May 2022 to 9 December 2025.
On the open market, the record shows 1 purchase worth €16k and 4 sales worth €17k. The net balance comes to €1,249 on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 3 share grants. In 2025 alone, the filings show no purchases and 1 sale.
The record was last updated on 10 December 2025 with a transaction in Adverum Biotechnologies, Inc. The last purchase on record was published on 24 May 2022, which is 1,614 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations